Zhitong Finance App News, Pharmaceutical Juno-B (02126.HK) announced that the company's core product Benodat® (rekiolense injection) was officially included in the 2026 edition of the National Basic Medical Insurance Drug Catalogue (NRDL). From January 1, 2027, patients who are covered by national health insurance payments can use Benoda® and enjoy basic medical insurance reimbursement according to regulations. This medical insurance payment covers the three approved indications of Benoda®, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Benoda® included in the national basic medical insurance catalogue is RMB 288,600.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Pharmaceutical Juno-B (02126.HK) announced that the company's core product Benodat® (rekiolense injection) was officially included in the 2026 edition of the National Basic Medical Insurance Drug Catalogue (NRDL). From January 1, 2027, patients who are covered by national health insurance payments can use Benoda® and enjoy basic medical insurance reimbursement according to regulations. This medical insurance payment covers the three approved indications of Benoda®, including large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The price of Benoda® included in the national basic medical insurance catalogue is RMB 288,600.